

1 **Positive and negative affect, related mental health traits, and cognitive**  
2 **performance: shared genetic architecture and potential causality**

3 Chloe Slaney<sup>1,2</sup>, Naoise Mac Giollabhui<sup>3</sup>, Peter J. van der Most<sup>4</sup>, Ensor R. Palacios<sup>1</sup>, Harold  
4 Snieder<sup>4</sup>, Michel Nivard<sup>1</sup>, Gibran Hemani<sup>1</sup>, Catharina A. Hartman<sup>5\*</sup>, Golam M. Khandaker<sup>1,2,6,7\*</sup>.

5

6 <sup>1</sup> Medical Research Council Integrative Epidemiology Unit, Bristol Medical School, University of  
7 Bristol, UK.

8 <sup>2</sup> Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School,  
9 University of Bristol, UK.

10 <sup>3</sup> Depression Clinical & Research Program, Department of Psychiatry, Massachusetts General  
11 Hospital, USA.

12 <sup>4</sup> Department of Epidemiology, University of Groningen, University Medical Center Groningen,  
13 the Netherlands.

14 <sup>5</sup> Interdisciplinary Center Psychopathology and Emotion Regulation, Department of Psychiatry,  
15 University of Groningen, University Medical Center Groningen, the Netherlands.

16 <sup>6</sup> NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS  
17 Foundation Trust and University of Bristol, UK.

18 <sup>7</sup> Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, UK.

19

20 \*Joint Senior Author

21

22 **Corresponding author:** Dr Chloe Slaney, MRC Integrative Epidemiology Unit, University of  
23 Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, Email: [chloe.slaney@bristol.ac.uk](mailto:chloe.slaney@bristol.ac.uk).

24

25 **Word count:**

26 Abstract: 323

27 Manuscript: 5,691 (includes tables/figure titles/footnotes)

28

29 **Keywords:** Positive Affect; Negative Affect; Depression; Anxiety; Cognition; General Cognitive  
30 Ability; Lifelines Cohort; GWAS; Genetic Correlation; Mendelian randomization.

31

32

33

34

35 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

36

## Abstract

37           Altered affect and cognitive dysfunction are transdiagnostic, burdensome, and  
38 pervasive features of many psychiatric conditions which remain poorly understood and  
39 have few efficacious treatments. Research on the genetic architecture of these  
40 phenotypes and causal relationships between them may provide insight into their  
41 aetiology and comorbidity. Using data from the Lifelines Cohort Study, we conducted  
42 genome-wide association studies (GWAS) on positive and negative affect and four  
43 cognitive domains (working memory, reaction time, visual learning and memory,  
44 executive function). Using publicly available large GWAS on related - albeit distinct-  
45 phenotypes (depression, anxiety, wellbeing, general cognitive ability [GCA]) we  
46 conducted genetic correlation and Mendelian randomization (MR) analyses to examine  
47 genetic overlap and causal relationships. We identified one genome-wide hit ( $p < 5 \times 10^{-8}$ )  
48 for reaction time, and many loci with suggestive associations ( $p < 5 \times 10^{-6}$ ; N range= 11-20  
49 independent hits) for other phenotypes. For most phenotypes, gene mapping and  
50 tissue expression analysis of suggestive hits from the GWAS showed increased gene  
51 expression in brain tissue compared to other tissues. As predicted, negative affect is  
52 genetically correlated with mental health phenotypes (depression  $r_g = 0.51$ ; anxiety  
53  $r_g = 0.70$ ; wellbeing  $r_g = -0.71$ ) and cognitive domains are genetically correlated with GCA  
54 and brain volume ( $r_g \leq 0.66$ ). Genetic correlations between negative and positive affect  
55 suggest that they are dissociable constructs ( $r_g = -0.18$ ) with negative affect having  
56 higher genetic overlap with GCA than positive affect ( $r_g = -0.19$  vs  $-0.06$ ). This could  
57 indicate that negative affect has a higher shared neural basis with GCA than positive  
58 affect and/or GCA and negative affect may exhibit causal relationships. MR analyses  
59 suggest potential causal effects of higher GCA on reduced negative affect, reduced risk  
60 of depression and anxiety, and higher wellbeing, but little impact on positive affect. We  
61 also report evidence for potential causal effects of depression and lower wellbeing on  
62 reduced GCA. Taken together, these results suggests that GCA may be a valid target for  
63 negative affect (but not positive affect) and depression and wellbeing may be valid  
64 targets for GCA.

65

66

## 67 1. Introduction

68 Positive and negative affect reflect the extent to which a person feels positive or  
69 negative emotions (e.g., excited, interested; nervous, distressed), respectively. Positive  
70 and negative affect can be experienced in a state (temporary) or trait (stable) manner  
71 (Watson et al., 1988) and are distinct transdiagnostic features of many health  
72 conditions, particularly depression and anxiety. Another critical yet often overlooked  
73 transdiagnostic feature of many health conditions is cognitive dysfunction (Colwell et  
74 al., 2022; Hilton et al., 2024). Despite altered affect and cognitive dysfunction being  
75 burdensome and pervasive features of many conditions, they remain poorly understood  
76 and have few efficacious treatments (Colwell et al., 2022; Rush et al., 2006).

77 Understanding the genetic architecture of mental health and cognitive  
78 phenotypes, and their relation to each other, can provide aetiological and biological  
79 insights which may facilitate identification of novel treatment targets (Carey et al., 2021;  
80 Minikel et al., 2024). Although observational studies have found associations between  
81 mental health and cognition (Dam et al., 2021; Rock et al., 2014; Zainal & Newman,  
82 2021; although see Ball et al., 2024;), causality remains unclear (Suddell et al., 2023).  
83 Reported associations may reflect: (1) poorer mental health causing poorer cognition,  
84 (2) poorer cognition causing poorer mental health, (3) confounding via shared risk  
85 factors (e.g., stress, sedentary behaviour) (Mac Giollabhui, 2021). Crucially, studies  
86 testing causal relationships between more narrowly defined mental health phenotypes  
87 (e.g., affect) and cognitive domains (e.g., memory, attention) are needed (Chavez-  
88 Baldini et al., 2023). Evidence of bidirectional causality would strengthen the case that  
89 targeting poor mental health (either diagnostic conditions or transdiagnostic  
90 phenotypes) may prevent and treat cognitive dysfunction, and *vice versa*. Two  
91 approaches that can shed light on the aetiology, comorbidity, and/or causal  
92 relationships between phenotypes are genetic correlations (using all genome-wide  
93 variants) (Bulik-Sullivan, Finucane, et al., 2015) and Mendelian randomization (MR)  
94 (typically using genome-wide association study hits) (Davey Smith & Ebrahim, 2003).  
95 MR can test for causality given certain assumptions are met (see Supplementary  
96 Methods). It does this by using genetic variants robustly associated with the exposure  
97 as a proxy for it. The properties of genetic variants (random assignment from parents,  
98 fixed at conception) mean that they are less likely to be associated with confounders  
99 and overcome issues of reverse causality (Davey Smith & Ebrahim, 2003; Sanderson et  
100 al., 2022). These methods provide powerful tools given the availability of large genome-  
101 wide association studies (GWAS) on well-defined phenotypes.

102 To date, GWAS on mental health phenotypes have largely been conducted on  
103 diagnostic categories such as depression and anxiety (Carey et al., 2021). However,  
104 these conditions are heterogeneous, with diagnosed individuals showing diverse  
105 symptom profiles. For example, a diagnosis of depression requires  $\geq 5/9$  diverse  
106 symptoms to be present within a two-week period, one of which must be low mood or  
107 anhedonia (Regier et al., 2013). In addition, symptoms are often not specific to a  
108 condition, meaning that GWAS on a condition may in reality capture a broader

109 phenotype. One potential approach to reducing phenotypic heterogeneity while  
110 addressing the overlap with other conditions, is to focus on *more narrowly defined* traits  
111 that more closely map onto biological systems (positive and negative affect, specific  
112 cognitive domains) (Wendt et al., 2020). In line with the Research Domain Criteria  
113 framework (Cuthbert, 2014; Insel et al., 2010), these are often transdiagnostic. GWAS  
114 on these more narrowly defined transdiagnostic traits may potentially facilitate insights  
115 into aetiology, comorbidity, and novel therapeutics.

116 In this study, we first conducted GWAS of negative and positive affect (assessed  
117 using the Positive and Negative Affect Schedule [PANAS]) and cognitive task  
118 performance in several domains (executive function, working memory, visual learning  
119 and memory, and reaction time). Second, we conducted gene mapping and tissue  
120 expression analysis to gain greater insight into associated genetic variants. Third, we  
121 investigated genetic overlap between mental health (negative affect, positive affect,  
122 depression, anxiety, wellbeing) and cognitive (general cognitive ability [GCA], specific  
123 cognitive domains) phenotypes using genetic correlations. Fourth, we tested evidence  
124 of potential causality between mental health and cognitive phenotypes using MR  
125 analyses. This is the first GWAS conducted on positive and negative affect using well-  
126 validated measures of these phenotypes. To achieve this, we use a large Dutch  
127 population-based cohort, the Lifelines Cohort. The application of MR to test evidence of  
128 causal relationships between affect and cognition is critical for improving our  
129 conceptual understanding of these phenotypes.

130 We hypothesised that: (i) follow-up analyses on all GWAS show increased gene  
131 expression in brain tissue compared to other tissues; (ii) affect and cognitive measures  
132 in the Lifelines Cohort genetically correlate with related (albeit distinct) phenotypes  
133 from external GWAS. Specifically, negative affect positively correlates with  
134 depression/anxiety and negatively correlates with wellbeing (reverse direction for  
135 positive affect), and higher cognitive performance on all domains correlates with GCA;  
136 (iii) there are bidirectional causal relationships between mental health and cognitive  
137 phenotypes.

138

139

140

141

142


143

144

145

146

147 **Figure 1. Study Objectives.**



148

## 149 2. Methods and Materials

150

### 151 2.1. Description of the Lifelines Cohort

152 Lifelines is a multi-disciplinary prospective population-based cohort study  
 153 examining in a unique three-generation design the health and health-related behaviours  
 154 of 167,729 persons living in the north of the Netherlands. It employs a broad range of  
 155 investigative procedures in assessing the biomedical, socio-demographic, behavioural,  
 156 physical and psychological factors which contribute to the health and disease of the  
 157 general population, with a special focus on multi-morbidity and complex genetics.  
 158 Participants were recruited between 2006-2013 via their GP (49%), participating family  
 159 members (38%), and self-registration on the Lifelines website (13%) (Scholtens et al.,  
 160 2015). Exclusion criteria for GP recruitment were: insufficient knowledge of Dutch  
 161 language, severe psychiatric or physical illness, limited life expectancy (<5 years)  
 162 (Scholtens et al., 2015). Baseline data included approximately: 15,000 children (0-17  
 163 years), 140,000 adults (18-65 years), 12,000 elderly individuals (65+ years). Following  
 164 baseline, participants completed follow-up questionnaires every 1.5 years and study  
 165 visits every 5 years (1st follow-up visit [2014-2017], 2nd follow-up visit [2019-2023])  
 166 (Scholtens et al., 2015; Sijtsma et al., 2022). In this study, we included participants ≥18  
 167 years who were genotyped on a GWAS array and excluded participants who have  
 168 conditions with a significant cognitive sequel: Alzheimer’s disease, other dementia,

169 epilepsy, multiple sclerosis, Parkinson's disease, and stroke.

170

## 171 2.2. *Assessment of Positive and Negative Affect*

172 The Positive and Negative Affect Scale (PANAS) was used. PANAS assesses  
173 positive and negative affect using two separate sub-scales, each containing 10 items  
174 (example items: excited, upset, nervous) (Crawford & Henry, 2004; Watson et al., 1988).  
175 Participants rate the extent they experienced each item during the last four weeks on a  
176 five-point scale (ranging from 'not at all' to 'extremely'). The outcome is the summed  
177 score on each subscale, which ranges from 10-50 (higher values reflect higher positive  
178 or negative affect). The scales have high internal consistency ( $\alpha=.87$ ) and moderate test-  
179 retest reliability over 8-weeks (positive  $r=.58$ ; negative  $r=.48$ ) (Watson et al., 1988).

180

## 181 2.3. *Assessment of Cognitive Performance*

182 Ruff Figural Fluency Test (RFFT) was used, which is a valid and reliable measure  
183 of executive functioning (Ross, 2014). The task consists of five parts, each containing 35  
184 identical five-dot patterns. Participants draw as many unique designs as possible within  
185 one minute by connecting dots in different patterns (Kuiper et al., 2017). The primary  
186 outcome is total number of unique designs.

187 Four tasks from the CogState Test Battery were administered in Lifelines, which  
188 tap into specific cognitive domains: visual learning & memory (one card learning task),  
189 reaction time/attention (identification task and detection task) and working memory  
190 (one-back task). As the detection and identification task both assess reaction time, we  
191 include only the identification task in this study which has a larger sample size. We used  
192 the recommended primary outcomes for all tasks. All outcomes were transformed  
193 (reaction time [ms] on the identification task was log<sub>10</sub> transformed, and accuracy on  
194 the one-back and one card learning task were arcsine transformed). On both memory  
195 tasks, higher values reflect better memory; on the reaction time task higher values  
196 reflect poorer performance (i.e., slower reaction time). See Supplementary Methods for  
197 further information on dataset preparation.

198

## 199 2.4. *Genetics Data and Quality Control*

200 Genotyping was conducted using three chip arrays in three subsets of the  
201 Lifelines cohort: (i) Illumina CytoSNP-12 Bead Chip v2 array (N=17,033), (ii) Infinium  
202 Global Screening Array (GSA) Beadchip-24 v1.0 (N=38,030), (iii) FinnGen Thermo Fisher  
203 Axiom® custom array (Affymetrix; N=29,166). See Supplementary for quality control  
204 (QC) and imputation procedures conducted by Lifelines. Following Lifelines QCs,  
205 73,086 participants were potentially eligible for this study (CytoSNP N=14,942; GSA  
206 N=31,810; Affymetrix N=26,334). We applied additional QCs, removing: (i) duplicates  
207 (individuals genotyped on >1 chip) and 1st-degree relatives between chips, (ii) non-  
208 European individuals, and (iii) genetic outliers, see Supplementary Figure S1. Following



209 additional QCs, 58,713 participants with genetics data were included in this study  
210 (CytoSNP N=7,632; GSA N=24,975; Affymetrix N=26,106).  
211

## 212 2.5. GWAS Summary Statistics for Related Mental Health and Cognitive Phenotypes

213 To examine genetic overlap and potential causality between affect and cognitive  
214 performance, we used summary statistics from large publicly available GWAS of  
215 depression (N Cases=294,322; N Controls=741,438) (Als et al., 2023), anxiety (N  
216 Cases=7,016; N Controls=14,745)(Otowa et al., 2016), wellbeing (N=2,370,390)  
217 (Baselmans et al., 2019), general cognitive ability (GCA; N=373,617)(Lam et al., 2021),  
218 and brain volume (N=47,316) (Jansen et al., 2020). See Supplementary Methods and  
219 Table S1-S2 for further details on these GWAS.  
220

## 221 2.6. Statistical Analyses

### 222 2.6.1. GWAS of Negative Affect, Positive Affect, and Cognitive Performance in Lifelines

223 We conducted GWAS (negative affect score, positive affect score, and cognitive  
224 performance score on each task) in each genotyped subset separately using REGENIE,  
225 which accounts for relatedness (Mbatchou et al., 2021). Prior to conducting GWAS,  
226 within each subset, we standardised all outcomes (mean=0; SD=1) and used PLINK  
227 (Purcell et al., 2007) to clean the genetics data for REGENIE Step 1. We included  
228 variants that met the following criteria: call rate (0.95), Hardy-Weinberg equilibrium (1e-  
229 6), minor allele count (100), minor allele frequency (0.01), not multi-allelic; and  
230 restricted to individuals with low missingness (0.95). In each GWAS, covariates included  
231 age, sex, and top 10 genetic principal components. We excluded poorly imputed  
232 variants (INFO score <0.8). For each outcome, we meta-analysed GWAS across the  
233 three subsets using STDERR model in METAL and applied genomic corrections (Willer et  
234 al., 2010). GWAS quality was inspected using GWAS Inspector 1.6.4.0 (Ani et al., 2021).  
235 The standard p-value threshold of  $5 \times 10^{-8}$  was used to determine genome-wide  
236 significance (for suggestive significance: p-value  $< 5 \times 10^{-6}$ ). Variants with MAF < 0.01 were  
237 excluded from all follow-up analyses.

### 238 2.6.2. Tissue Specificity of Prioritised Genes

239 We used gene and tissue mapping to explore associated variants in each GWAS.  
240 We used an online platform (FUMA) which integrates resources to annotate, prioritize,  
241 and visualise the summary statistics (Watanabe et al., 2017). The SNP2GENE function  
242 was used to annotate SNPs and prioritise genes at each locus using positional  
243 mapping. Using these prioritised genes, we used GENE2FUNC to investigate tissue  
244 specificity of differentially expressed gene (DEG) sets using GTEx v8 data on 54 non-  
245 diseased tissue types (N≤838 adults). For further details, see Supplementary Methods.

### 246 2.6.3. Genetic Correlations

247 Linkage Disequilibrium Score Regression (LDSR) (Bulik-Sullivan et al., 2015;  
248 Bulik-Sullivan et al., 2015) was used to estimate genetic correlations of mental health

249 and cognitive phenotypes. This included phenotypes from Lifelines (positive and  
250 negative affect, cognitive performance), and phenotypes from large external GWAS  
251 (depression, anxiety, wellbeing, GCA, brain volume). We used precomputed LD scores  
252 calculated using 1000G European data. As low imputation quality may confound LDSR  
253 we filtered to HapMap3 panel SNPs which tend to be well-imputed in most studies  
254 (Bulik-Sullivan, Finucane, et al., 2015). If GWAS did not have a sample size column for  
255 SNPs, we assumed the same sample size for all SNPs. We checked all phenotypes had  
256 heritability z-scores  $> 4$  in line with standard procedure (Bulik-Sullivan et al., 2015). For  
257 LDSR cleaning filters applied, see (Bulik-Sullivan et al., 2015).  
258

## 259 2.7. Bidirectional Mendelian Randomization

260 MR was performed to investigate potential causal effect of mental health  
261 phenotypes on cognition and *vice versa*. This was done in R v4.2.2 using *TwoSampleMR*  
262 (Hemani et al., 2017) and *CAUSE* v1.2.0.0335 (Morrison et al., 2020).

263 We applied the following criteria to identify genetic instruments: (1)  $p < 5 \times 10^{-8}$  (if  
264 not available, a lenient  $p < 5 \times 10^{-6}$  threshold was used) (2) independent ( $r^2 < 0.01$ , kb =  
265 1000; based on European clustering in the 1000 genomes reference panel using  
266 *ld\_clump()* in the *ieugwasr* package (Hemani et al., 2024)), (3) minor allele frequency  
267 (MAF)  $\geq 1\%$ . Any SNPs not available in the outcome GWAS were excluded. For primary  
268 analyses, we used the Inverse-Variance Weighted method ( $> 1$  SNP available) or Wald  
269 ratio (if only 1 SNP was available). Where multiple genetic variants were available, we  
270 conducted sensitivity analyses using different MR methods which have different  
271 assumptions regarding the validity of the genetic instruments: MR-Egger (Bowden et al.,  
272 2015), weighted median (Bowden et al., 2016), weighted mode (Hartwig et al., 2017).

273 We also applied Steiger filtering to assess whether genetic variants have stronger  
274 associations with exposures than outcomes (Hemani et al., 2017). Given the possibility  
275 of correlated pleiotropy, we additionally applied causal analysis using summary effect  
276 estimates (CAUSE) which accounts for correlated and uncorrelated pleiotropy  
277 (Morrison et al., 2020). For CAUSE, we included genome-wide variants pruned using  
278 default criteria ( $r^2 = 0.01$ , p-value = 0.003) based on European 1000 genomes reference  
279 panel. Given the possibility of population-level confounding (e.g., dynastic effects), we  
280 also conducted within-sibship MR in the MR-base platform (Hemani et al., 2018) using  
281 publicly available within-sibship GWAS on wellbeing, depressive symptoms, and  
282 cognitive ability (Howe et al., 2022); see Supplementary methods for more detail. We  
283 also checked for heterogeneity (Cochran's Q-statistic) and pleiotropy (Egger intercept).  
284 For further details on assumptions of different MR methods used here, see  
285 Supplementary methods.

286 In our primary analysis, we included phenotypes which have well-powered  
287 GWAS as exposures ( $> 1$  SNP available: depression, wellbeing, GCA). In secondary  
288 analysis, we included phenotypes which have less well-powered GWAS as exposures (1



289 SNP or lenient p-value criteria: anxiety, negative affect, positive affect) to investigate  
290 whether similar patterns of effects are observed for these phenotypes.

### 291 3. Results

292

#### 293 3.1. GWAS of Negative Affect, Positive Affect, and Cognitive Performance in the 294 Lifelines Cohort

295 No SNPs met genome-wide significance threshold ( $p < 5 \times 10^{-8}$ ), except one SNP for  
296 reaction time (rs2920287, MAF=0.04,  $p = 1.907 \times 10^{-8}$ ). Visual inspection of the locus zoom  
297 plot of the region around rs2920287 shows many nearby genes, with PSCA being in  
298 closest proximity (Figure S4). Follow-up analyses of this SNP using the GWAS Catalog  
299 did not show associations with any traits. Lowering the threshold to  $p < 5 \times 10^{-6}$  yielded  
300 associated SNPs for all phenotypes (Table 1). For Manhattan plots, see Figures S2-S3.

301 **Table 1.** GWAS Results of Positive Affect, Negative Affect, and Cognitive Performance in  
302 the Lifelines cohort.

Phenotype	N	Hits ( $p < 5 \times 10^{-8}$ )	Hits Clumped (1000kb, $r^2 = 0.01$ )	Hits ( $p < 5 \times 10^{-6}$ )	Hits Clumped (1000kb, $r^2 = 0.01$ )
Positive affect	57,946	0	0	67	20
Negative affect	57,946	0	0	73	15
Executive function	36,563	0	0	108	12
Visual learning and memory	36,783	0	0	139	12
Reaction time	35,729	1	1	176	19
Working memory	36,349	0	0	56	11

303 Note: Variants with MAF < 0.01 excluded.

304

#### 305 3.2. Tissue Specificity of Prioritised Genes

306 We used a lenient p-value threshold ( $p < 5 \times 10^{-6}$ ) to identify SNPs for follow-up  
307 analysis in FUMA. For all phenotype's, prioritised genes were upregulated across  
308 multiple tissue types, particularly brain tissue (see Supplementary Figures S5-S6 and  
309 Tables S18-S23). Following FUMAs default Bonferroni corrections for multiple  
310 comparisons, there was significant upregulation in brain tissue for positive affect  
311 (substantia nigra) and visual learning and memory (cerebellum and cerebellar  
312 hemispheres) compared to other tissue types. For visualisation of tissue specificity of  
313 prioritised genes, see Figures S5-S6.

314

315

316 **3.3. Genetic Correlations between Affect and Mental Health Phenotypes**

317 **3.3.1. Negative Affect is Genetically Correlated with Mental Health Phenotypes**

318 Negative affect score was genetically correlated with depression ( $r_g = 0.51$   
 319 [SE=0.05],  $p=2.80E-28$ ), wellbeing ( $r_g = -0.71$  [SE=0.05],  $p=8.65E-41$ ), and anxiety ( $r_g =$   
 320  $0.70$  [SE=0.18],  $p=0.0002$ ). Positive affect showed weaker genetic correlations with  
 321 depression ( $r_g = -0.11$  [SE=0.04],  $p=0.005$ ), wellbeing ( $r_g = 0.30$  [SE=0.05],  $p=2.38E-09$ ),  
 322 with little evidence for anxiety ( $r_g = -0.16$  [SE=0.17],  $p=0.33$ ).

323 **3.3.2. Cognitive Domains are Genetically Correlated with GCA**

324 Cognitive performance in Lifelines tasks were genetically correlated with the  
 325 largest GWAS for GCA: executive function ( $r_g=0.66$  [SE=0.07],  $p=1.39E-23$ ), visual  
 326 learning & memory ( $r_g=0.54$  [SE=0.05],  $p=6.90E-29$ ), working memory ( $r_g=0.53$  [SE=0.06],  
 327  $p=1.23E-18$ ), and reaction time ( $r_g= -0.39$  [SE=0.06],  $p=1.48E-12$ ).


328 **3.3.3. Compared to Positive Affect, Negative Affect has Stronger Genetic Correlation  
 329 with GCA.**

330 There was a weak negative genetic correlation between positive and negative  
 331 affect scores ( $r_g = -0.18$  [SE=0.08],  $p=0.016$ ). There was stronger evidence of genetic  
 332 correlations between GCA and negative affect ( $r_g = -0.19$  [SE=0.04],  $p=7.56E-06$ )  
 333 compared to GCA and positive affect ( $r_g = -0.06$  [SE=0.04],  $p=0.18$ ).

334 For all results, see Figure 2 and Supplementary Table S3.

335

336 **Figure 2.** Genetic correlations between Lifelines phenotypes (negative affect, positive  
 337 affect, cognitive performance) and external phenotypes (depression, anxiety, wellbeing,  
 338 GCA, brain volume) using LDSR.



339  
 340

GCA=General Cognitive Ability; EF=Executive Functioning; Memory=Visual Learning and Memory; Neg Affect=Negative Affect (PANAS); Pos Affect=Positive Affect (PANAS).

341

### 342 3.4. Potential Causal Effects: Results from Mendelian Randomization

#### 343 3.4.1. Effect of Mental Health Phenotypes on Cognition

344 In primary analyses, across all MR methods there was consistent evidence for a  
345 potential causal effect of depression on lower GCA (IVW estimate: -0.14 [95% CI= -0.19  
346 to -0.09],  $p=0.00000006$ ) and of one SD increase in wellbeing on higher GCA (IVW  
347 estimate: 0.30 [95% CI= 0.13 to 0.46],  $p=0.0004$ ) (Figure 3). These effects remained after  
348 applying Steiger Filtering (Figure 4; Supplementary Tables S6-S9) and were supported by  
349 MR CAUSE (Supplementary Table S24-S25). There was also evidence for a potential  
350 causal effect of one SD increase in wellbeing on better executive functioning (IVW  
351 estimate: 0.24 [95% CI= 0.03 to 0.44],  $p=0.024$ ), and weak evidence of an effect on  
352 memory (IVW estimate: 0.19 [95% CI= -0.02 to 0.41],  $p=0.076$ ). However, these effects  
353 were not consistent across MR methods and were not supported following Steiger  
354 filtering (Figure 4; Supplementary Tables S6-S9).

355 In secondary analyses, there was evidence for a potential causal effect of one  
356 SD increase in negative affect on poorer memory (IVW estimate: -0.15 [95% CI= -0.27 to  
357 -0.03],  $p=0.012$ ) and one SD increase in positive affect on better executive functioning  
358 (IVW estimate: 0.16 [95% CI= 0.02 to 0.30],  $p=0.024$ ). However, these effects were not  
359 consistent across MR methods, see Figures 4 and Supplementary Tables S10-S13.

360 For other mental health and cognitive phenotypes, there was little evidence of  
361 causality based on IVW estimates (Figures 4; Supplementary Tables S6-S14).  
362 Confidence intervals (CIs) using within-sibship GWAS were very large with imprecise  
363 estimates (Figure S16).

364 There was evidence of heterogeneity, with the strongest evidence in analyses of  
365 depression and wellbeing on GCA, see Supplementary Table S15. There was little  
366 evidence of horizontal pleiotropy (based on Egger Intercept;  $ps \geq 0.14$ ), except for weak  
367 evidence in MR analyses of depression on GCA ( $p=0.084$ ) and executive function  
368 ( $p=0.048$ ); see Supplementary Table S16.

369

#### 370 3.4.2. Effect of GCA on Mental Health Phenotypes

371 There was evidence for a potential causal effect of one SD increase in GCA on  
372 lower negative affect (IVW estimate: -0.11 [95% CI= -0.16 to -0.05],  $p=0.0002$ ), reduced  
373 risk of depression (OR: 0.88 [95% CI=0.83 to 0.93],  $p=0.00003$ ), and anxiety (OR: 0.64  
374 [95% CI=0.51 to 0.81],  $p=0.0002$ ), and higher wellbeing (IVW estimate: 0.02 [95% CI=  
375 0.01 to 0.04],  $p=0.011$ ) (Figure 3; Supplementary Table S4). However, effects were not  
376 consistent across all MR methods: there was more consistent evidence for GCA on  
377 negative affect (3/4 methods provide evidence supporting causality) compared to  
378 depression (2/4), anxiety (2/4), and wellbeing (1/4).

379 Following Steiger Filtering, there was still evidence for a potential causal effect of  
380 one SD increase in GCA on lower negative affect (IVW estimate: -0.07 [95% CI= -0.11 to  
381 -0.02],  $p=0.007$ ) but weaker evidence for one SD increase in GCA on reduced risk of

382 anxiety (IVW estimate: -0.24 [95% CI= -0.50 to 0.02],  $p=0.072$ ), although CIs were large  
383 (see Figure 4 and Supplementary Table S5). For GCA on depression and wellbeing,  
384 results were unaltered as no variants were removed in Steiger Filtering. MR CAUSE  
385 support that the data are consistent with a causal effect of GCA on negative affect,  
386 depression, and wellbeing (See Supplementary Tables S24-S25). Although MR CAUSE  
387 suggests the data for GCA on anxiety fit the causal model better than the null or sharing  
388 model, this did not meet conventional  $p$ -value criteria ( $p>0.05$ ). In within-sibship MR, CI  
389 were very large with imprecise estimates (Figure S16).


390           There was strong evidence of heterogeneity in MR analyses testing effects of  
391 GCA on mental health phenotypes, except for GCA on anxiety ( $p=0.34$ ); see  
392 Supplementary Table S15. There was little evidence of horizontal pleiotropy based on  
393 MR Egger Intercept ( $p_s \geq .15$ ) (Supplementary Table S16).

394

395

396


397 **Figure 3.** Mendelian Randomization Analyses Testing Evidence of Potential Causality  
 398 between Mental Health and Cognition Phenotypes.



399  
 400 *Note: Bars reflect 95% CIs. Axes differ to ensure inclusion of CIs for all analyses. For binary phenotypes (anxiety, depression), beta reflects log(OR).*  
 401  
 402



403 **Figure 4.** Steiger Filtered Mendelian Randomization Analyses Testing Evidence of  
404 Potential Causality between Mental Health and Cognition Phenotypes.



405  
406 *Note: Bars reflect 95% CIs. Axes differ to increase visibility of results in different analyses; CI of MR-Egger (cognition on anxiety) is absent on graph due to very*  
407 *large CI. For binary phenotypes (anxiety, depression), beta reflects log(OR).*

408  
409  
410

## 411 4. Discussion

412 We conducted genome-wide association studies (GWAS) on negative and  
413 positive affect using a well-validated scale (PANAS) and four cognitive domains  
414 (executive function, working memory, visual learning and memory, reaction time) in the  
415 Lifelines Cohort. We identified one genome-wide hit ( $p < 5 \times 10^{-8}$ ) for reaction time, and  
416 many loci with suggestive associations ( $p < 5 \times 10^{-6}$ ) for other phenotypes. As predicted,  
417 gene mapping and tissue expression analysis of suggestive hits show higher gene  
418 expression in brain tissue compared to other tissues for most phenotypes; negative  
419 affect is genetically correlated with mental health phenotypes (depression  $r_g = 0.51$ ;  
420 anxiety  $r_g = 0.70$ ; wellbeing  $r_g = -0.71$ ) and cognitive domains are genetically correlated  
421 with GCA and brain volume ( $r_g \leq 0.66$ ). Genetic correlations between negative and  
422 positive affect suggest that they are dissociable constructs ( $r_g = -0.18$ ); with negative  
423 affect having higher genetic overlap with GCA than positive affect ( $r_g = -0.19$  vs  $-0.06$ ).  
424 Importantly, MR results suggest evidence of potential causal effects of higher GCA on  
425 reduced negative affect, reduced risk of depression and anxiety, and higher wellbeing  
426 (with the most robust result being higher GCA on reduced negative affect), but little  
427 impact of GCA on positive affect. We also report evidence for potential causal effects of  
428 depression and lower wellbeing on reduced GCA. Taken together, these results suggests  
429 that GCA may be a valid target for reducing negative affect, but not for increasing  
430 positive affect; and depression and wellbeing may be valid targets for GCA.

### 431 4.1. Potential Causality between Mental Health and Cognitive Phenotypes

432 Across different MR methods, we found evidence of a potential causal effect of  
433 higher GCA on many mental health outcomes (reduced negative affect, reduced risk of  
434 depression and anxiety, increased wellbeing). There was also evidence of potential  
435 causal effects of depression and wellbeing on GCA. Whilst we did not observe evidence  
436 for negative affect and anxiety on GCA, given the consistent direction of effect, this may  
437 be due to these GWAS being smaller and having decreased statistical power when used  
438 as exposures. Our findings complement recent studies using MR analyses and  
439 complementary designs (e.g., within-sibship analyses) reporting evidence of causality  
440 between mental health phenotypes (depression, wellbeing, and/or anxiety) and  
441 constructs related to cognition [e.g., educational attainment (Demange et al., 2024),  
442 education duration (Van De Weijer et al., 2024)].

443 However, few studies have directly tested causality between mental health and  
444 cognition. Using MR analyses in the ALSPAC cohort, Suddell et al. (2023) tested  
445 causality between mental health conditions (depression, anxiety) and specific cognitive  
446 domains (response inhibition, working memory, emotion recognition) but reported that  
447 estimates were imprecise likely due to limited statistical power (Suddell et al., 2023).  
448 Marchi et al. (2024) used multivariable MR to test the causal effect of GCA and poverty  
449 on several mental health conditions (including depression and anxiety) (Marchi et al.,  
450 2024). After adjusting for poverty, they found evidence that higher GCA may causally  
451 reduce risk of depression and anxiety. Through inclusion of additional GWAS (negative  
452 affect, positive affect, larger depression GWAS), our findings lend support to these

453 findings and additionally suggest: (1) higher GCA may also cause lower negative affect  
454 (but not influence positive affect), (2) evidence of bidirectional effects (i.e., higher risk of  
455 depression and lower wellbeing may also cause poorer GCA). Taken together, these MR  
456 findings suggest a potential bidirectional causal relationship between mental health  
457 and cognition.

458 Whilst our results could indicate a bidirectional causal effect, other explanations  
459 (which violate MR assumptions) may account for these results including: (1) correlated  
460 pleiotropy and (2) population-level confounding. Correlated pleiotropy occurs when  
461 genetic variants used in MR analyses affect both the exposure and outcome via a  
462 shared heritable factor (Morrison et al., 2020). An example of how this could occur here  
463 is through genetic variants impacting brain-related processes (e.g., synaptic plasticity)  
464 which directly affect both cognition and mental health. Whilst we did include several  
465 MR methods which allow for some correlated pleiotropy (e.g., weighted median,  
466 weighted mode, MR CAUSE) (Morrison et al., 2020), these methods could still give  
467 biased estimates (and lead to incorrect conclusions regarding causality) if the *majority*  
468 of instruments exhibit correlated pleiotropy. Another factor which may account for  
469 these results is population-level confounding (e.g., assortative mating, dynastic effects)  
470 (Brumpton et al., 2020). Whilst we are interested in direct effects from GWAS (i.e.,  
471 genetic variants effect on phenotypic variation), for many phenotypes GWAS will also  
472 pick up indirect effects (e.g., dynastic effects: parental genotype affecting offspring  
473 phenotype via environmental factors). This is problematic as it violates MR assumptions  
474 and could lead to incorrect conclusions (Brumpton et al., 2020). One approach  
475 proposed to overcome this is to use within-family GWAS (Brumpton et al., 2020; Howe  
476 et al., 2022). Howe et al. (2022) found that GWAS estimates for some phenotypes,  
477 including cognitive ability and depressive symptoms, were attenuated when using  
478 within-sibship GWAS compared to population-level GWAS (Howe et al., 2022). To try to  
479 address this, we also conducted MR using within-sibship GWAS (depressive symptoms,  
480 wellbeing, and cognitive ability) to test whether this impacted our findings.  
481 Unfortunately, confidence intervals (CIs) were very large with imprecise estimates  
482 (Supplementary Methods and Figure S16). This is unsurprising given the much smaller  
483 sample size of within-sibship GWAS compared to population-level GWAS and highlights  
484 the need for larger within-family GWAS on complex phenotypes like cognitive ability and  
485 depressive symptoms.

#### 486 4.2. *Additional Insights from Genetic Analyses on Negative and Positive Affect, and* 487 *Cognitive Performance.*

488 Genetic correlation analyses reveal key insights into the genetic architecture of  
489 these phenotypes. First, as predicted, there was moderate genetic overlap between  
490 negative affect and mental health phenotypes (depression  $r_g=0.51$ ; anxiety  $r_g=0.70$ ;  
491 wellbeing  $r_g = -0.71$ ), and between cognitive domains and cognition-related phenotypes  
492 (GCA, brain volume;  $r_g \leq 0.66$ ). This suggests that although these phenotypes are  
493 related, they are not interchangeable but rather have partly distinct genetic  
494 components. Second, as expected based on phenotypic correlations, genetic

495 correlation between negative and positive affect suggest they are dissociable  
496 constructs as opposed to being opposite ends of the same spectrum ( $r_g = -0.18$ )  
497 (Watson et al., 1988). Third, compared to positive affect, negative affect has higher  
498 genetic overlap with GCA ( $r_g = -0.19$  vs  $-0.06$ ). This could indicate that negative affect has  
499 a higher shared neural basis with GCA than positive affect and/or GCA and negative  
500 affect may exhibit causal relationships (as suggested by our MR results).

501 Despite the negative affect GWAS having a much smaller sample size than the  
502 depression GWAS (N=57,946 versus N=1,035,760), when used as an outcome, we  
503 found more consistent evidence that GCA may play a causal role in negative affect  
504 across MR methods. Speculatively, this may be because the GWAS on negative affect  
505 consists of a more homogeneous phenotype which may increase statistical power and  
506 impact effect estimates (Manchia et al., 2013). This highlights the importance of future  
507 studies conducting GWAS on more homogeneous phenotypes (Nagel et al., 2018).  
508 Whilst we focused on transdiagnostic features of positive and negative affect and  
509 specific cognitive domains, there is a need for GWAS on other transdiagnostic features  
510 [e.g., sleep disturbances, anhedonia, hot cognition (Roiser & Sahakian, 2013)]. It is  
511 likely that advances will also be gained by parsing heterogeneity using other  
512 approaches. For example, GWAS on depressed patients with specific characteristics  
513 [e.g., immune-metabolic depression (Milaneschi et al., 2020)]. Research focusing on  
514 improving the validity of subtypes within and across psychiatric conditions will be  
515 necessary for advancing our understanding of these conditions (Hammen, 2018).

#### 516 4.3. *Limitations*

517 Limitations of this study must be considered when interpreting the results. First,  
518 smaller sample sizes for some GWAS resulted in a lack of genome-wide significant  
519 variants ( $p < 5 \times 10^{-8}$ ) and/or larger CIs in MR analyses (positive and negative affect,  
520 specific cognitive domains, anxiety). Consortia combining data from several large  
521 datasets are necessary to provide well-powered GWAS on these phenotypes; our GWAS  
522 in the Lifelines Cohort will provide a useful contribution to this endeavour. Second, MR  
523 estimates lifetime effect of an exposure (e.g., depression) on an outcome (e.g., GCA)  
524 (Sanderson et al., 2022). Whilst this study is informative for understanding lifetime risk,  
525 it is unclear what time periods would be best to intervene on. This requires either a  
526 randomised controlled trial (RCT; which would be expensive and time consuming) or MR  
527 with large GWAS on exposures and outcomes at specific ages in the lifespan (Power et  
528 al., 2023). Third, cognitive performance is highly related to other socioeconomic  
529 phenotypes (e.g., education, socioeconomic status). Future studies testing  
530 independent effects and interactions between these phenotypes on mental health  
531 using other methods (e.g., multivariable MR) would be useful (see Marchi et al., 2024).  
532 Fourth, as discussed above, observed bidirectional causal relationships in MR analyses  
533 between mental health and GCA could instead be due to violation of MR assumptions.  
534 Triangulating results from standard MR analyses with other methods (e.g., within-  
535 sibship MR) may help to increase confidence in conclusions drawn. Fifth, many GWAS  
536 use data from large population-based cohorts which are less representative of some

537 populations (e.g., less affluent people) which may hinder generalizability of the findings.  
538 Sixth, for continuous variables (e.g., GCA, negative affect, wellbeing), our study cannot  
539 shed light on whether these relationships are nonlinear. As currently available nonlinear  
540 MR approaches have provided implausible results (Wade et al., 2023), there is a need  
541 for other methods to be used to characterise the shape of these relationships (see  
542 Pines et al., 2024). Seventh, we focus on a subset of phenotypes, future studies should  
543 expand this to provide insight into other mental health and cognitive phenotypes which  
544 may show different relationships (e.g., schizophrenia, hot cognition) (Danahauer et al.,  
545 2013). Finally, many GWAS on psychiatric conditions do not exclude people with  
546 comorbidities. For example, the depression GWAS includes UK Biobank which defines  
547 depression based on the following question: “Have you ever seen a general practitioner  
548 (or psychiatrist) for nerves, anxiety, tension, or depression?”. This may result in many  
549 individuals with anxiety being characterised as having depression and makes it  
550 challenging to conduct subsequent analyses testing genetic overlap/causality between  
551 different conditions.

#### 552 4.4. *Implications*

553 Our GWAS on positive and negative affect and cognitive domains in the Lifelines  
554 Cohort provide valuable resources which may facilitate insights into aetiology,  
555 comorbidity, and causal risk factors for these phenotypes. We found evidence of  
556 potential causal relationships between mental health phenotypes (negative affect,  
557 depression, anxiety, wellbeing) and GCA. This may suggest that strategies targeting poor  
558 mental health may prevent/treat cognitive dysfunction, and *vice versa*. However, to  
559 increase confidence in this finding, triangulation using other methods which have  
560 different strengths/limitations to MR, and consideration of highly related phenotypes  
561 (e.g., education), are needed. Additionally, GWAS on other transdiagnostic phenotypes  
562 are necessary to enable clearer insights into potential causal relationships. If multiple  
563 lines of evidence support causality, careful consideration of potential interventions  
564 (e.g., age to intervene, length of intervention, whether interventions targeting  
565 depression to reduce poorer GCA [or *vice versa*] could also have their own direct effect  
566 of GCA) would be necessary. This could have important implications for clinical  
567 practice (e.g., targeting depression may help prevent/treat cognitive impairments in  
568 health conditions such as dementia; cognitive remediation therapy may help  
569 prevent/treat depression). Considering the broader literature (Demange et al., 2024;  
570 Marchi et al., 2024), policy changes targeting factors impacting GCA [e.g., education  
571 (Anderson et al., 2020)] would potentially be promising for reducing future mental  
572 health challenges in the general population.

573 Nevertheless, there is also evidence suggesting that cognitive impairments can  
574 persist in remitted depressed individuals (Semkovska et al., 2019). This may appear to  
575 contrast the idea that treating depression may help to prevent/treat cognitive  
576 impairments. Speculatively, this could be because: (1) once depressive symptoms have  
577 decreased, cognitive impairments reduce but require a longer time to observe effects  
578 (RCTs may not have long enough follow-up lengths), (2) reducing depression may help



579 to prevent cognitive impairments, but may not help treat them once they are already  
580 experienced (i.e., a ‘scar effect’), (3) treating depression may improve cognition in a  
581 subset of people (not all individuals), and/or (4) some symptoms of depression when  
582 treated may improve cognition (but not all symptoms when treated will improve  
583 cognition). There is a need for research testing these different theories to better  
584 understand the dynamic relationship between depression and cognition.

#### 585 4.5. *Conclusions*

586 In summary, we conducted GWAS on transdiagnostic features of many health  
587 conditions (positive and negative affect, four specific cognitive domains). We identified  
588 one genome-wide hit ( $p < 5 \times 10^{-8}$ ) for reaction time, and many loci with suggestive  
589 associations ( $p < 5 \times 10^{-6}$ ) for other cognitive phenotypes. Follow-up gene mapping and  
590 tissue expression analyses of suggestive hits show higher gene expression in brain  
591 tissue compared to other tissues for most phenotypes. Genetic correlation analyses  
592 show that negative and positive affect are dissociable constructs, with negative affect  
593 having higher genetic overlap with GCA than positive affect. Importantly, in MR  
594 analyses, we found evidence of a potential causal effect of higher GCA on multiple  
595 mental health phenotypes (reduced negative affect, depression, and anxiety; and  
596 increased wellbeing), with little evidence on positive affect. We also report evidence of  
597 potential causal effects of depression and lower wellbeing on reduced GCA. Taken  
598 together, as the most robust evidence was for GCA on negative affect, with little effect  
599 on positive affect, this suggests that GCA may be a valid target for negative affect (but  
600 not positive affect) and depression and wellbeing may be valid targets for GCA. Further  
601 research testing the relationship between depression and cognition using  
602 complementary research designs is warranted, particularly there is a need for studies to  
603 test different theories we proposed in the discussion.

604

## 605 **Acknowledgements**

606 The generation and management of GWAS genotype data for the Lifelines Cohort Study  
607 is supported by the UMCG Genetics Lifelines Initiative (UGLI). UGLI is partly supported  
608 by a Spinoza Grant from NWO, awarded to Cisca Wijmenga. The authors wish to  
609 acknowledge the services of the Lifelines Cohort Study, the contributing research  
610 centers delivering data to Lifelines, and all the study participants.

611 The Genotype-Tissue Expression (GTEx) Project was supported by the [Common Fund](#) of  
612 the Office of the Director of the National Institutes of Health, and by NCI, NHGRI,  
613 NHLBI, NIDA, NIMH, and NINDS. The final data used for the analyses described in this  
614 manuscript were obtained from: the GTEx Portal via FUMA on 01/07/2024 and  
615 18/07/2024.

## 616 **Ethics approval**

617 The general Lifelines protocol has been approved by the UMCG Medical ethical  
618 committee under number 2007/152.

## 619 **Funding**

620 The Lifelines initiative has been made possible by subsidy from the Dutch Ministry of  
621 Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University  
622 Medical Center Groningen (UMCG), Groningen University and the Provinces in the North  
623 of the Netherlands (Drenthe, Friesland, Groningen).

624 This work was supported by a UK Medical Research Council (MRC) grant to GMK  
625 (MC\_UU\_00032/06) which forms part of the Integrative Epidemiology Unit (IEU) at the  
626 University of Bristol. The grant also supports CS. NMG acknowledges funding support by  
627 Harvard University's Mind Brain Behavior Interfaculty Initiative and National Institute of  
628 Mental Health grant K23MH132893. GMK acknowledges additional funding support  
629 from the Wellcome Trust (201486/Z/16/Z and 201486/B/16/Z), MRC (MR/W014416/1;  
630 MR/S037675/1; and MR/Z50354X/1), and the UK National Institute of Health and Care  
631 Research (NIHR) Bristol Biomedical Research Centre (NIHR 203315). GH is supported  
632 by the MRC (MC\_UU\_00032/01), and the NIHR Bristol Biomedical Research Centre  
633 (NIHR 203315). The views expressed are those of the authors and not necessarily those  
634 of the NIHR or the Department of Health and Social Care, UK.

## 635 **Contributions**

636 CS, GK, CH, NMG and GH conceptualized and designed the study. CS analyzed the data  
637 and drafted the manuscript. All authors advised on the project/analysis and approved  
638 the final version of the manuscript.

## 639 **Conflicts of Interest**

640 No conflicts of interest were reported.

641

642

643

## References

- 644 Als, T. D., Kurki, M. I., Grove, J., Voloudakis, G., Therrien, K., Tasanko, E., Nielsen, T. T.,  
645 Naamanka, J., Veerapen, K., Levey, D. F., Bendl, J., Bybjerg-Grauholm, J., Zeng, B.,  
646 Demontis, D., Rosengren, A., Athanasiadis, G., Bækved-Hansen, M., Qvist, P.,  
647 Bragi Walters, G., ... Børglum, A. D. (2023). Depression pathophysiology, risk  
648 prediction of recurrence and comorbid psychiatric disorders using genome-wide  
649 analyses. *Nature Medicine*, 29(7), 1832–1844.
- 650 Anderson, E. L., Howe, L. D., Wade, K. H., Ben-Shlomo, Y., Hill, W. D., Deary, I. J.,  
651 Sanderson, E. C., Zheng, J., Korologou-Linden, R., Stergiakouli, E., Davey Smith, G.,  
652 Davies, N. M., & Hemani, G. (2020). Education, intelligence and Alzheimer's  
653 disease: evidence from a multivariable two-sample Mendelian randomization  
654 study. *International Journal of Epidemiology*, 49(4), 1163–1172.
- 655 Ani, A., Van Der Most, P. J., Snieder, H., Vaez, A., & Nolte, I. M. (2021). GWASinspector:  
656 comprehensive quality control of genome-wide association study results.  
657 *Bioinformatics (Oxford, England)*, 37(1), 129–130.
- 658 Ball, E. L., Morillo, L., Poyner, E., McIntosh, A. M., & Iveson, M. H. (2024). Cognitive  
659 ability in early life and risk of depression in adulthood: A systematic review and  
660 meta-analysis. *Journal of Affective Disorders*, 352, 498–508.
- 661 Baselmans, B. M. L., Jansen, R., Ip, H. F., van Dongen, J., Abdellaoui, A., van de Weijer,  
662 M. P., Bao, Y., Smart, M., Kumari, M., Willemsen, G., Hottenga, J. J., Boomsma, D.  
663 I., de Geus, E. J. C., Nivard, M. G., & Bartels, M. (2019). Multivariate genome-wide  
664 analyses of the well-being spectrum. *Nature Genetics*, 51(3), 445–451.
- 665 Brumpton, B., Sanderson, E., Heilbron, K., Hartwig, F. P., Harrison, S., Vie, G. Å., Cho,  
666 Y., Howe, L. D., Hughes, A., Boomsma, D. I., Havdahl, A., Hopper, J., Neale, M.,  
667 Nivard, M. G., Pedersen, N. L., Reynolds, C. A., Tucker-Drob, E. M., Grotzinger, A.,  
668 Howe, L., ... Davies, N. M. (2020). Avoiding dynastic, assortative mating, and  
669 population stratification biases in Mendelian randomization through within-family  
670 analyses. *Nature Communications* 2020 11:1, 11(1), 1–13.
- 671 Bulik-Sullivan, B., Finucane, H. K., Anttila, V., Gusev, A., Day, F. R., Loh, P. R., Duncan,  
672 L., Perry, J. R. B., Patterson, N., Robinson, E. B., Daly, M. J., Price, A. L., & Neale, B.  
673 M. (2015). An atlas of genetic correlations across human diseases and traits.  
674 *Nature Genetics* 2015 47:11, 47(11), 1236–1241.
- 675 Bulik-Sullivan, B., Loh, P. R., Finucane, H. K., Ripke, S., Yang, J., Patterson, N., Daly, M.  
676 J., Price, A. L., Neale, B. M., Corvin, A., Walters, J. T. R., Farh, K. H., Holmans, P. A.,  
677 Lee, P., Collier, D. A., Huang, H., Pers, T. H., Agartz, I., Agerbo, E., ... O'Donovan, M.  
678 C. (2015). LD Score regression distinguishes confounding from polygenicity in  
679 genome-wide association studies. *Nature Genetics* 2015 47:3, 47(3), 291–295.
- 680 Carey, C., Strong, R., Huang, Y., Aslibekyan, S., Gentleman, R., Smoller, J., Wilmer, J.,  
681 Robinson, E., & Germine, L. (2021). Shared and Distinct Genetic Influences  
682 Between Cognitive Domains and Psychiatric Disorder Risk Based on Genome-  
683 Wide Data. *Biological Psychiatry*, 89(9), S45–S46.

- 684 Chavez-Baldini, U., Nieman, D. H., Keestra, A., Lok, A., Mocking, R. J. T., De Koning, P.,  
685 Krzhizhanovskaya, V. V., Bockting, C. L. H., Van Rooijen, G., Smit, D. J. A.,  
686 Sutterland, A. L., Verweij, K. J. H., Van Wingen, G., Wigman, J. T. W., Vulink, N. C., &  
687 Denys, D. (2023). The relationship between cognitive functioning and  
688 psychopathology in patients with psychiatric disorders: a transdiagnostic network  
689 analysis. *Psychological Medicine*, 53(2), 476.
- 690 Colwell, M. J., Tagomori, H., Chapman, S., Gillespie, A. L., Cowen, P. J., Harmer, C. J., &  
691 Murphy, S. E. (2022). Pharmacological targeting of cognitive impairment in  
692 depression: recent developments and challenges in human clinical research.  
693 *Translational Psychiatry* 2022 12:1, 12(1), 1–16.
- 694 Crawford, J. R., & Henry, J. D. (2004). The positive and negative affect schedule  
695 (PANAS): construct validity, measurement properties and normative data in a large  
696 non-clinical sample. *The British Journal of Clinical Psychology*, 43(Pt 3), 245–265.
- 697 Cuthbert, B. N. (2014). The RDoC framework: facilitating transition from ICD/DSM to  
698 dimensional approaches that integrate neuroscience and psychopathology. *World*  
699 *Psychiatry*, 13(1), 28–35.
- 700 Dam, V. H., Stenbæk, D. S., Köhler-Forsberg, K., Ip, C., Ozenne, B., Sahakian, B. J.,  
701 Knudsen, G. M., Jørgensen, M. B., & Frokjaer, V. G. (2021). Hot and cold cognitive  
702 disturbances in antidepressant-free patients with major depressive disorder: a  
703 NeuroPharm study. *Psychological Medicine*, 51(14), 2347–2356.
- 704 Danhauer, S. C., Legault, C., Bandos, H., Kidwell, K., Costantino, J., Vaughan, L., Avis,  
705 N. E., Rapp, S., Coker, L. H., Naughton, M., Naylor, C., Terracciano, A., &  
706 Shumaker, S. (2013). Positive and negative affect, depression, and cognitive  
707 processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR)  
708 Trial. *Neuropsychology, Development, and Cognition. Section B, Aging,*  
709 *Neuropsychology and Cognition*, 20(5), 532–552.
- 710 Davey Smith, G., & Ebrahim, S. (2003). “Mendelian randomization”: Can genetic  
711 epidemiology contribute to understanding environmental determinants of  
712 disease? *International Journal of Epidemiology*, 32(1), 1–22.
- 713 Demange, P. A., Boomsma, D. I., van Bergen, E., & Nivard, M. G. (2024). Educational  
714 attainment and psychiatric diagnoses: a national registry data and two-sample  
715 Mendelian randomization study. *Nature Mental Health* 2024 2:6, 2(6), 668–679.
- 716 Hammen, C. (2018). Risk Factors for Depression: An Autobiographical Review. *Annual*  
717 *Review of Clinical Psychology*, 14(Volume 14, 2018), 1–28.
- 718 Hemani, G., Elsworth, B., Palmer, T., & Rasteiro, R. (2024). *ieugwasr: Interface to the*  
719 *“OpenGWAS” Database API. R package version 1.0.1,*  
720 *<https://mrcieu.github.io/ieugwasr/>. <https://github.com/MRCIEU/ieugwasr>*
- 721 Hemani, Gibran, Tilling, K., & Davey Smith, G. (2017). Orienting the causal relationship  
722 between imprecisely measured traits using GWAS summary data. *PLOS Genetics*,  
723 13(11), e1007081.
- 724 Hemani, Gibran, Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin,

- 725 C., Burgess, S., Bowden, J., Langdon, R., Tan, V. Y., Yarmolinsky, J., Shihab, H. A.,  
726 Timpson, N. J., Evans, D. M., Relton, C., Martin, R. M., Davey Smith, G., Gaunt, T.  
727 R., & Haycock, P. C. (2018). The MR-base platform supports systematic causal  
728 inference across the human phenome. *ELife*, 7.
- 729 Hilton, R. A., Tozzi, L., Nesamoney, S., Kozłowska, K., Kohn, M. R., Harris, A., Clarke, S.,  
730 & Williams, L. M. (2024). Transdiagnostic neurocognitive dysfunction in children  
731 and adolescents with mental illness. *Nature Mental Health* 2024 2:3, 2(3), 299–  
732 309.
- 733 Howe, L. J., Nivard, M. G., Morris, T. T., Hansen, A. F., Rasheed, H., Cho, Y., Chittoor, G.,  
734 Ahlskog, R., Lind, P. A., Palviainen, T., van der Zee, M. D., Cheesman, R., Mangino,  
735 M., Wang, Y., Li, S., Klaric, L., Ratliff, S. M., Bielak, L. F., Nygaard, M., ... Davies, N.  
736 M. (2022). Within-sibship genome-wide association analyses decrease bias in  
737 estimates of direct genetic effects. *Nature Genetics* 2022 54:5, 54(5), 581–592.
- 738 Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., Sanislow, C., &  
739 Wang, P. (2010). Research Domain Criteria (RDoC): Toward a New Classification  
740 Framework for Research on Mental Disorders. *American Journal of Psychiatry*,  
741 167(7), 748–751.
- 742 Jansen, P. R., Nagel, M., Watanabe, K., Wei, Y., Savage, J. E., de Leeuw, C. A., van den  
743 Heuvel, M. P., van der Sluis, S., & Posthuma, D. (2020). Genome-wide meta-  
744 analysis of brain volume identifies genomic loci and genes shared with  
745 intelligence. *Nature Communications* 2020 11:1, 11(1), 1–12.
- 746 Lam, M., Chen, C.-Y., Ge, T., Xia, Y., Hill, D. W., Trampush, J. W., Yu, J., Knowles, E.,  
747 Davies, G., Stahl, E. A., Huckins, L., Liewald, D. C., Djurovic, S., Melle, I.,  
748 Christoforou, A., Reinvang, I., DeRosse, P., Lundervold, A. J., Steen, V. M., ... Lencz,  
749 T. (2021). Identifying nootropic drug targets via large-scale cognitive GWAS and  
750 transcriptomics. *Neuropsychopharmacology*, 17, 47.
- 751 Mac Giollabhui, N. (2021). Inflammation and depression: Research designs to better  
752 understand the mechanistic relationships between depression, inflammation,  
753 cognitive dysfunction, and their shared risk factors. *Brain, Behavior, & Immunity -*  
754 *Health*, 15.
- 755 Manchia, M., Cullis, J., Turecki, G., Rouleau, G. A., Uher, R., & Alda, M. (2013). The  
756 impact of phenotypic and genetic heterogeneity on results of genome wide  
757 association studies of complex diseases. *PloS One*, 8(10).
- 758 Marchi, M., Alkema, A., Xia, C., Thio, C. H. L., Chen, L. Y., Schalkwijk, W., Galeazzi, G.  
759 M., Ferrari, S., Pingani, L., Kweon, H., Evans-Lacko, S., David Hill, W., & Boks, M. P.  
760 (2024). Investigating the impact of poverty on mental illness in the UK Biobank  
761 using Mendelian randomization. *Nature Human Behaviour* 2024, 1–13.
- 762 Mbatchou, J., Barnard, L., Backman, J., Marcketta, A., Kosmicki, J. A., Ziyatdinov, A.,  
763 Benner, C., O'Dushlaine, C., Barber, M., Boutkov, B., Habegger, L., Ferreira, M.,  
764 Baras, A., Reid, J., Abecasis, G., Maxwell, E., & Marchini, J. (2021). Computationally  
765 efficient whole-genome regression for quantitative and binary traits. *Nature*  
766 *Genetics* 2021 53:7, 53(7), 1097–1103.



- 767 Milaneschi, Y., Lamers, F., Berk, M., & Penninx, B. W. J. H. (2020). Depression  
768 Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic  
769 Depression. *Biological Psychiatry*, 88(5), 369–380.
- 770 Minikel, E. V., Painter, J. L., Dong, C. C., & Nelson, M. R. (2024). Refining the impact of  
771 genetic evidence on clinical success. *Nature 2024* 629:8012, 629(8012), 624–629.
- 772 Morrison, J., Knoblauch, N., Marcus, J. H., Stephens, M., & He, X. (2020). Mendelian  
773 randomization accounting for correlated and uncorrelated pleiotropic effects using  
774 genome-wide summary statistics. *Nature Genetics 2020* 52:7, 52(7), 740–747.
- 775 Nagel, M., Watanabe, K., Stringer, S., Posthuma, D., & Van Der Sluis, S. (2018). Item-  
776 level analyses reveal genetic heterogeneity in neuroticism. *Nature*  
777 *Communications 2018* 9:1, 9(1), 1–10.
- 778 Otowa, T., Hek, K., Lee, M., Byrne, E. M., Mirza, S. S., Nivard, M. G., Bigdeli, T., Aggen, S.  
779 H., Adkins, D., Wolen, A., Fanous, A., Keller, M. C., Castelao, E., Kutalik, Z., Der  
780 Auwera, S. V., Homuth, G., Nauck, M., Teumer, A., Milaneschi, Y., ... Hettema, J. M.  
781 (2016). Meta-analysis of genome-wide association studies of anxiety disorders.  
782 *Molecular Psychiatry*, 21(10), 1391–1399.
- 783 Pines, A., Tozzi, L., Bertrand, C., Keller, A. S., Zhang, X., Whitfield-Gabrieli, S., Hastie, T.,  
784 Larsen, B., Leikauf, J., & Williams, L. M. (2024). Psychiatric Symptoms, Cognition,  
785 and Symptom Severity in Children. *JAMA Psychiatry*.
- 786 Power, G. M., Sanderson, E., Pagoni, P., Fraser, A., Morris, T., Prince, C., Frayling, T. M.,  
787 Heron, J., Richardson, T. G., Richmond, R., Tyrrell, J., Warrington, N., Davey Smith,  
788 G., Howe, L. D., & Tilling, K. M. (2023). Methodological approaches, challenges,  
789 and opportunities in the application of Mendelian randomisation to lifecourse  
790 epidemiology: A systematic literature review. *European Journal of Epidemiology*  
791 2023 39:5, 39(5), 501–520.
- 792 Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller,  
793 J., Sklar, P., De Bakker, P. I. W., Daly, M. J., & Sham, P. C. (2007). PLINK: A Tool Set  
794 for Whole-Genome Association and Population-Based Linkage Analyses. *American*  
795 *Journal of Human Genetics*, 81(3), 559.
- 796 Regier, D. A., Kuhl, E. A., & Kupfer, D. J. (2013). The DSM-5: Classification and criteria  
797 changes. *World Psychiatry*, 12(2), 92–98.
- 798 Rock, P. L., Roiser, J. P., Riedel, W. J., & Blackwell, A. D. (2014). Cognitive impairment in  
799 depression: A systematic review and meta-analysis. *Psychological Medicine*,  
800 44(10), 2029–2040.
- 801 Roiser, J. P., & Sahakian, B. J. (2013). Hot and cold cognition in depression. *CNS*  
802 *Spectrums*, 18(3), 139–149.
- 803 Ross, T. P. (2014). The reliability and convergent and divergent validity of the Ruff Figural  
804 Fluency Test in healthy young adults. *Archives of Clinical Neuropsychology : The*  
805 *Official Journal of the National Academy of Neuropsychologists*, 29(8), 806–817.
- 806 Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden,  
807 D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J.,

- 808 Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute  
809 and longer-term outcomes in depressed outpatients requiring one or several  
810 treatment steps: a STAR\*D report. *The American Journal of Psychiatry*, *163*(11),  
811 1905–1917.
- 812 Sanderson, E., Glymour, M. M., Holmes, M. V., Kang, H., Morrison, J., Munafò, M. R.,  
813 Palmer, T., Schooling, C. M., Wallace, C., Zhao, Q., & Davey Smith, G. (2022).  
814 Mendelian randomization. *Nature Reviews Methods Primers*, *2*(1), 1–21.
- 815 Scholtens, S., Smidt, N., Swertz, M. A., Bakker, S. J. L., Dotinga, A., Vonk, J. M., Van Dijk,  
816 F., Van Zon, S. K. R., Wijmenga, C., Wolffenbuttel, B. H. R., & Stolk, R. P. (2015).  
817 Cohort Profile: LifeLines, a three-generation cohort study and biobank.  
818 *International Journal of Epidemiology*, *44*(4), 1172–1180.
- 819 Semkowska, M., Quinlivan, L., O’Grady, T., Johnson, R., Collins, A., O’Connor, J., Knittle,  
820 H., Ahern, E., & Gload, T. (2019). Cognitive function following a major depressive  
821 episode: a systematic review and meta-analysis. *The Lancet Psychiatry*, *6*(10),  
822 851–861.
- 823 Sijtsma, A., Rienks, J., Van Der Harst, P., Navis, G., Rosmalen, J. G. M., & Dotinga, A.  
824 (2022). Cohort Profile Update: Lifelines, a three-generation cohort study and  
825 biobank. *International Journal of Epidemiology*, *51*(5), E295–E302.
- 826 Suddell, S., Mahedy, L., Skirrow, C., Penton-Voak, I. S., Munafò, M. R., & Wootton, R. E.  
827 (2023). Cognitive functioning in anxiety and depression: results from the ALSPAC  
828 cohort. *Royal Society Open Science*, *10*(8).
- 829 Van De Weijer, M. P., Demange, P. A., Pelt, D. H. M., Bartels, M., & Nivard, M. G. (2024).  
830 Disentangling potential causal effects of educational duration on well-being, and  
831 mental and physical health outcomes. *Psychological Medicine*, *54*(7), 1403–1418.
- 832 Wade, K. H., Hamilton, F. W., Carslake, D., Sattar, N., Davey Smith, G., & Timpson, N. J.  
833 (2023). Challenges in undertaking nonlinear Mendelian randomization. *Obesity*  
834 (*Silver Spring, Md.*), *31*(12), 2887–2890.
- 835 Watanabe, K., Taskesen, E., Van Bochoven, A., & Posthuma, D. (2017). Functional  
836 mapping and annotation of genetic associations with FUMA. *Nature*  
837 *Communications* *2017* *8*:1, *8*(1), 1–11.
- 838 Watson, D, Clark, L. A., & Tellegen, A. (1988). Development and validation of brief  
839 measures of positive and negative affect: the PANAS scales. *Journal of Personality*  
840 *and Social Psychology*, *54*(6), 1063–1070.
- 841 Watson, David, Clark, L. A., & Tellegen, A. (1988). Development and validation of brief  
842 measures of positive and negative affect: the PANAS scales. *Journal of Personality*  
843 *and Social Psychology*, *54*(6), 1063–1070.
- 844 Wendt, F. R., Pathak, G. A., Tylee, D. S., Goswami, A., & Polimanti, R. (2020).  
845 Heterogeneity and Polygenicity in Psychiatric Disorders: A Genome-Wide  
846 Perspective. *Chronic Stress*, *4*.
- 847 Willer, C. J., Li, Y., & Abecasis, G. R. (2010). METAL: fast and efficient meta-analysis of  
848 genomewide association scans. *Bioinformatics*, *26*(17), 2190.

849 Zainal, N. H., & Newman, M. G. (2021). Depression and worry symptoms predict future  
850 executive functioning impairment via inflammation. *Psychological Medicine*.  
851